← Leaderboards
Issam A Awad
University Of Colorado Denver
$18,526,491
Attributed
$23,120,370
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2007–24$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$23,120,370 · 11
By mechanism
R01$11,552,810 · 4
U01$3,797,989 · 1
R44$3,287,712 · 1
P01$3,127,349 · 2
R21$801,453 · 2
K24$553,057 · 1
Top collaborators
- Douglas A Marchuk13 shared
- Lisa J Mckerracher3 shared
- Rebecca A Stockton3 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Kristen Elizabeth Boyle$4,077,729
- Douglas K Graham$6,579,169
- Hae J Park$153,008
- Heidi Grabenstatter$858,016
Others in their field
Top investigators on “Blood Vessels”
- Sonia M Thomas · Research Triangle Institute$353,402,726
- Tracy L Nolen · Research Triangle Institute$353,402,726
- Charles Decarli · University Of California At Davis$66,498,201
- Josef Coresh · New York University School Of Medicine$63,693,760
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$62,000,770
- Robert P Kimberly · University Of Alabama At Birmingham$56,093,149
Research focus
Blood VesselsLesionHemorrhageGenotypeAmericanBrainBiological MarkersOperative Surgical ProceduresSignal TransductionCavernous HemangiomaIronPhenotypeAffectLinkMagnetic Resonance ImagingSomatic MutationMouse ModelLifetime RiskResectedGenesProteinsPreventResearch PersonnelCerebrum
Grant awards (50)
Biomarkers of Cerebral Cavernous Angioma with Symptomatic Hemorrhage (CASH)$584,415
R01 · FY2024 · NS · contact PI
Phenotyping, Human Tissue and Biomarkers Core$292,276
P01 · FY2024 · NS · contact PI
Biomarkers of Cerebral Cavernous Angioma with Symptomatic Hemorrhage (CASH)$636,184
R01 · FY2023 · NS · contact PI
Phenotyping, Human Tissue and Biomarkers Core$305,301
P01 · FY2023 · NS · contact PI
Biomarkers of Cerebral Cavernous Angioma with Symptomatic Hemorrhage (CASH) - Supplemental$201,805
R01 · FY2023 · NS · contact PI
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial$764,492
R01 · FY2022 · NS · contact PI
Trial Readiness in Cavernous Angiomas with Symptomatic Hemorrhage$718,152
U01 · FY2022 · NS · contact PI
Biomarkers of Cerebral Cavernous Angioma with Symptomatic Hemorrhage (CASH)$636,184
R01 · FY2022 · NS · contact PI
Phenotyping, Human Tissue and Biomarkers Core$309,388
P01 · FY2022 · NS · contact PI
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial$768,540
R01 · FY2021 · NS · contact PI
Trial Readiness in Cavernous Angiomas with Symptomatic Hemorrhage$744,602
U01 · FY2021 · NS · contact PI
Biomarkers of Cerebral Cavernous Angioma with Symptomatic Hemorrhage (CASH)$650,448
R01 · FY2021 · NS · contact PI
Phenotyping, Human Tissue and Biomarkers Core$313,270
P01 · FY2021 · NS · contact PI
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial$772,673
R01 · FY2020 · NS · contact PI
Trial Readiness in Cavernous Angiomas with Symptomatic Hemorrhage$745,943
U01 · FY2020 · NS · contact PI
Biomarkers of Cerebral Cavernous Angioma with Symptomatic Hemorrhage (CASH)$689,695
R01 · FY2020 · NS · contact PI
Phenotyping, Human Tissue and Biomarkers Core$323,159
P01 · FY2020 · NS · contact PI
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial$786,174
R01 · FY2019 · NS · contact PI
Trial Readiness in Cavernous Angiomas with Symptomatic Hemorrhage$747,027
U01 · FY2019 · NS · contact PI
Phenotyping and Human Tissue Core$314,820
P01 · FY2019 · NS · contact PI
Trial Readiness in Cavernous Angiomas with Symptomatic Hemorrhage$842,265
U01 · FY2018 · NS · contact PI
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial$806,009
R01 · FY2018 · NS · contact PI
Phenotyping and Human Tissue Core$314,820
P01 · FY2018 · NS · contact PI
Development of BA-1049 for treatment of cerebral cavernous malformation$1,576,432
R44 · FY2017 · NS
Phenotyping and Human Tissue Core$309,925
P01 · FY2017 · NS · contact PI
Development of BA-1049 for treatment of cerebral cavernous malformation$1,430,655
R44 · FY2016 · NS
Rock Inhibition as Therapy for Cerebral Cavernous Malformation$433,569
R01 · FY2016 · NS · contact PI
Phenotyping and Human Tissue Core$314,820
P01 · FY2016 · NS · contact PI
Development of BA-1049 for treatment of cerebral cavernous malformation$280,625
R44 · FY2016 · NS
Rock Inhibition as Therapy for Cerebral Cavernous Malformation$455,117
R01 · FY2015 · NS · contact PI
Phenotyping and Human Tissue Core$329,570
P01 · FY2015 · NS · contact PI
BIOMARKERS OF BRAIN PERMEABILITY IN HUMAN CEREBRAL CAVERNOUS MALFORMATIONS$237,000
R21 · FY2015 · NS · contact PI
Rock Inhibition as Therapy for Cerebral Cavernous Malformation$473,253
R01 · FY2014 · NS · contact PI
BIOMARKERS OF BRAIN PERMEABILITY IN HUMAN CEREBRAL CAVERNOUS MALFORMATIONS$197,500
R21 · FY2014 · NS · contact PI
Rock Inhibition as Therapy for Cerebral Cavernous Malformation$447,296
R01 · FY2013 · NS · contact PI
Rock Inhibition as Therapy for Cerebral Cavernous Malformation$459,797
R01 · FY2012 · NS · contact PI
Genesis and Progression of Cerebral Cavernous Malformations$457,386
R01 · FY2012 · NS
Genesis and Progression of Cerebral Cavernous Malformations$476,791
R01 · FY2011 · NS
Genesis and Progression of Cerebral Cavernous Malformations$479,794
R01 · FY2010 · NS
Genesis and Progression of Cerebral Cavernous Malformations$88,629
R01 · FY2010 · NS
Genesis and Progression of Cerebral Cavernous Malformations$484,559
R01 · FY2009 · NS
IMMUNE RESPONSE IN HUMAN CEREBRAL CAVERNOUS MALFORMATIONS$166,797
R21 · FY2008 · NS · contact PI
IMMUNE RESPONSE IN HUMAN CEREBRAL CAVERNOUS MALFORMATIONS$200,156
R21 · FY2007 · NS · contact PI
PHENOTYPE-GENOTYPE IN GEREBRAL VASCULAR MALFORMATIOINS$115,626
K24 · FY2004 · NS
PHENOTYPE-GENOTYPE IN GEREBRAL VASCULAR MALFORMATIOINS$106,066
K24 · FY2003 · NS
PHENOTYPE-GENOTYPE IN GEREBRAL VASCULAR MALFORMATIOINS$6,979
K24 · FY2003 · NS
PHENOTYPE-GENOTYPE IN GEREBRAL VASCULAR MALFORMATIOINS$110,538
K24 · FY2002 · NS
PHENOTYPE-GENOTYPE IN GEREBRAL VASCULAR MALFORMATIOINS$108,105
K24 · FY2001 · NS
PHENOTYPE-GENOTYPE IN GEREBRAL VASCULAR MALFORMATIOINS$61,819
K24 · FY2000 · NS
PHENOTYPE-GENOTYPE IN GEREBRAL VASCULAR MALFORMATIOINS$43,924
K24 · FY2000 · NS